Other languages LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Delayed Nasdaq Other stock markets 10:12:27 2024-05-20 am EDT			5-day change	1st Jan Change
2.7 ^USD	+2.27%		-11.76%	+70.89%

Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20
LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 20
LAVA Therapeutics N.V. Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052	Mar. 05
Sector Update: Health Care Stocks Softer Late Afternoon	Jan. 25
Sector Update: Health Care Stocks Slipping Thursday Afternoon	Jan. 25
Sector Update: Health Care	Jan. 25
Lava Therapeutics to Study Gammabody Combined With Merck's Keytruda to Treat Metastatic Prostate Cancer	Jan. 25
Upbeat US Economic Growth Data Lift Sentiment, Driving Premarket Gains for US Equity Futures	Jan. 25
Top Premarket Gainers	Jan. 25
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc. to Evaluate LAVA-1207 in Combination with KEYTRUDA	Jan. 25
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16
LAVA Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22
Lava Therapeutics to Halt LAVA-051 Clinical Trial, Focus on Potential Prostate Cancer Treatment LAVA-1207	23-06-14
LAVA Therapeutics N.V. Provides Updates on Clinical Programs and Extends the Cash Runway	23-06-14
LAVA Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-08
Sector Update: Health Care Stocks Rising Late Friday	23-06-02
Sector Update: Health Care	23-06-02
Top Midday Gainers	23-06-02
Top Premarket Gainers	23-06-02
LAVA Therapeutics Shares Rise Premarket Following Selection by Janssen Biotech to Support Development of Cancer Treatment	23-06-02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Other languages

Filters